Here are the Form 4 insider transactions from DFP Holdings Ltd (DFPH) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow DFPH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DFPH filings page.
Oncology Institute, Inc. (TOI) reported changes in ownership by an affiliated investment group on a joint Form 4. The reporting persons, including entities related to M33 Growth, are identified as directors of the company.
On November 18, 2025, TOI M, LLC made an in-kind distribution of 590,892 shares of TOI common stock to its members, including 11,818 shares to M33 Growth I L.P. ("M33 LP"). Also on that date, M33 LP made an in-kind distribution of 2,500,000 shares of TOI common stock to its limited partners. After these transactions, one line in the table shows 7,944,207 shares and another shows 5,444,207 shares beneficially owned, both marked as directly held.
The transactions are coded as "J" (other) and reflect reallocations of shares among affiliated funds rather than open-market purchases or sales.
The Oncology Institute, Inc. (TOI) reported that its Chief Executive Officer acquired additional common stock through a stock-based award. On 11/17/2025, the officer received 6,464 shares of common stock at a stated price of $0.00 per share, increasing their directly held stake to 1,799,984 shares.
The filing explains that these 6,464 shares represent restricted stock units (RSUs) that were fully vested upon grant, after shares were withheld to cover tax obligations. This is a routine equity compensation event that aligns the CEO’s interests more closely with those of other shareholders.
Oncology Institute, Inc. (TOI) reported an insider equity transaction by a person serving as Chief Medical Officer on a Form 4. On 11/17/2025, this reporting person acquired 2,086 shares of common stock at $0.00 per share. These shares represent restricted stock units that were fully vested upon grant and delivered net of withholding tax obligations.
After this transaction, the reporting person directly beneficially owns 237,930 shares of Oncology Institute common stock.
Oncology Institute, Inc. (TOI) reported an equity award to its Chief Financial Officer, who is an officer and reporting person of the company. On 11/17/2025, the CFO acquired 195 shares of common stock as restricted stock units (RSUs) that were fully vested upon grant, with no cash price shown for the shares. After this transaction, the officer beneficially owned 235,369 shares of TOI common stock in direct ownership. The RSUs were net of shares withheld to cover tax obligations.
Oncology Institute (TOI) Chief Executive Officer Daniel Virnich reported an insider equity award. The Form 4 shows 6,211 shares of common stock acquired at $0.00 on 11/12/2025, reflecting RSUs that were fully vested upon grant and settled net of withholding taxes. Following this transaction, he beneficially owned 1,793,520 shares, held directly.
Oncology Institute, Inc. (TOI) insider activity: A Form 4 reports that the company’s Chief Medical Officer acquired common stock via restricted stock units (RSUs) that were fully vested upon grant on 11/12/2025.
The filing lists two RSU-related acquisitions at a price of $0.00 per share: 306 shares and 1,202 shares, reported as net of withholding tax obligations. Following these transactions, the reporting person beneficially owned 235,844 shares.